9 research outputs found

    Combined absence of TRP53 target genes ZMAT3, PUMA and p21 cause a high incidence of cancer in mice

    No full text
    Transcriptional activation of target genes is essential for TP53-mediated tumour suppression, though the roles of the diverse TP53-activated target genes in tumour suppression remains poorly understood. Knockdown of ZMAT3, an RNA-binding zinc-finger protein involved in regulating alternative splicing, in haematopoietic cells by shRNA caused leukaemia only with the concomitant absence of the PUMA and p21, the critical effectors of TRP53-mediated apoptosis and cell cycle arrest respectively. We were interested to further investigate the role of ZMAT3 in tumour suppression beyond the haematopoietic system. Therefore, we generated Zmat3 knockout and compound gene knockout mice, lacking Zmat3 and p21, Zmat3 and Puma or all three genes. Puma-/-p21-/-Zmat3-/- triple knockout mice developed tumours at a significantly higher frequency compared to wild-type, Puma-/-Zmat3-/- or p21-/-Zmat3-/-deficient mice. Interestingly, we observed that the triple knockout and Puma-/-Zmat3-/- double deficient animals succumbed to lymphoma, while p21-/-Zmat3-/- animals developed mainly solid cancers. This analysis suggests that in addition to ZMAT3 loss, additional TRP53-regulated processes must be disabled simultaneously for TRP53-mediated tumour suppression to fail. Our findings reveal that the absence of different TRP53 regulated tumour suppressive processes changes the tumour spectrum, indicating that different TRP53 tumour suppressive pathways are more critical in different tissues.This work was supported by grants and fellowships from the Australian Phenomics Network (APN), the Australian National Health and Medical Research Council (NHMRC) to MJH and AS (1143105), Programme Grant to AS (1016701), Investigator grant to AS (2007887), Investigator Grant to MJH (2017971); the Leukaemia and Lymphoma Society of America to AS and MJH (LLS SCOR 7015-18); the Cancer Council of Victoria Project grant to AS (1052309) and Venture Grant to MJH and AS; support to AS from the estate of Anthony (Toni) Redstone OAM; support to AJ from Spanish Ministry of Economy and Development Grant (PID2021-127710OB-I00) and Programa Captació de Talent Investigador ‘La Caixa’ foundation (51110009). AJ is supported by Ramon y Cajal Research Fellowship (RYC2018-025244-I), AS and MJH are supported by NHMRC Fellowships (1020363 and 1156095), MSB is supported by Cancer Council Victoria Postdoctoral Fellowship and Swedish Cancer Society (21 0355 PT). This work was made possible through the Victorian Government Operational Infrastructure Support and Australian Government, the ‘Unidad de Excelencia María de Maeztu’ funded by the Spanish Government

    Mutant TRP53 exerts a target gene-selective dominant-negative effect to drive tumor development

    No full text
    Mutations in Trp53, prevalent in human cancer, are reported to drive tumorigenesis through dominant-negative effects (DNEs) over wild-type TRP53 function as well as neomorphic gain-of-function (GOF) activity. We show that five TRP53 mutants do not accelerate lymphomagenesis on a TRP53-deficient background but strongly synergize with c-MYC overexpression in a manner that distinguishes the hot spot Trp53 mutations. RNA sequencing revealed that the mutant TRP53 DNE does not globally repress wild-type TRP53 function but disproportionately impacts a subset of wild-type TRP53 target genes. Accordingly, TRP53 mutant proteins impair pathways for DNA repair, proliferation, and metabolism in premalignant cells. This reveals that, in our studies of lymphomagenesis, mutant TRP53 drives tumorigenesis primarily through the DNE, which modulates wild-type TRP53 function in a manner advantageous for neoplastic transformation

    Methylation of all BRCA1 copies predicts response to the PARP inhibitor rucaparib in ovarian carcinoma

    No full text
    Around 10% of high-grade serous ovarian carcinomas (HGSOC) harbor BRCA1 promoter methylation, but it is uncertain how it predicts response to PARP inhibition. Here, the authors show that homozygous BRCA1 methylation predicts response to rucaparib while heterozygous methylation of BRCA1 predicts resistance in HGSOC

    Abnormal Nuclear pore formation triggers apoptosis in the intestinal epithelium of elys-Deficient zebrafish

    No full text
    Background & Aims: Zebrafish mutants generated by ethylnitrosourea-mutagenesis provide a powerful toot for dissecting the genetic regulation of developmental processes, including organogenesis. One zebrafish mutant, "flotte lotte" (flo), displays striking defects in intestinal, liver, pancreas, and eye formation at 78 hours postfertilization (hpf). In this study, we sought to identify the underlying mutated gene in flo and link the generic lesion to its phenotype. Methods: Positional cloning was employed to map the flo mutation. Subcellular characterization of flo embryos was achieved using histology, immunocytochemistry, bromodeoxyuridine incorporation analysis, and confocal and electron microscopy. Results: The molecular lesion in flo is a nonsense mutation in the elys (embryonic large molecule derived from yolk sac) gene, which encodes a severely truncated protein lacking the Elys C-terminal AT-hook DNA binding domain. Recently, the human ELYS protein has been shown to play a critical, and hitherto unsuspected, role in nuclear pore assembly. Although elys messenger RNA (mRNA) is expressed broadly during early zebrafish development, widespread early defects in flo are circumvented by the persistence of maternally expressed elys mRNA until 24 hpf From 72 hpf, elys mRNA expression is restricted to proliferating tissues, including the intestinal epithelium, pancreas, liver, and eye. Cells in these tissues display disrupted nuclear pore formation; ultimately, intestinal epithelial cells undergo apoptosis. Conclusions: Our results demonstrate that Elys regulates digestive organ formation
    corecore